the value of the platform seems to be in finding variables in the trial design they can change to increase the probability of success.
given the exorbitant cost in time and money of trials and the very high failure rates I would think pharma companies could be greatly interested in this type of technology
Ann: Pause in Trading, page-15
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.609M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 577791 | 2.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.7¢ | 379629 | 2 |
View Market Depth
| Last trade - 16.12pm 12/07/2024 (20 minute delay) ? |
| OPL (ASX) Chart |
Day chart unavailable